

Baltic Biomaterials Centre of Excellence



New knowledge
and experience



More qualified
scientists and
experts



Modern
infrastructure

- Increased number of scientific projects
- Increased ratio of highly cited publications
- Patient-centred approach
- More scientific services for industry
- Individual approach in treatment
- New products for industry
- Attracting enterprises in healthcare for the Baltic Region
- Attracting more international scientists and students
- New startups
- Modern study programmes
- Attracting competitive funding and contract research funds



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 857287

Baltic Biomaterials Centre of Excellence,
Headquarters at Riga Technical University, Riga, Latvia
bbcentre.eu

BBCE coordinator:
Prof. Janis Locs
Pulka street 3,
Riga LV-1007, Latvia
+371 67089211
vkti.rtu.lv
janis.locs@rtu.lv

Baltic Biomaterials Centre of Excellence Research Directions

Strategic research direction of Baltic Biomaterials Centre of Excellence (BBCE) is development of patient specific personalized solutions for bone regeneration in 3 levels: biomaterial composition, geometry and bioactive compound delivery.

Full cycle of biomaterials for bone regeneration development consists of continuous steps:

1. Development of biodegradable, osteoconductive and osteoinductive materials, composites and drug delivery systems.
2. Preclinical in vitro/in vivo investigations.
3. Clinical trials.

BBCE long-term goal


A joint Baltic Biomaterials Centre of Excellence for advanced biomaterials development based on the long-term strategic cooperation within consortium






Group 1 – Calcium phosphates and composites

- Calcium phosphate (CaP) nanoparticles, nanosuspensions, granules, bone cements, CaP/biodegradable polymer (e.g. Polylactic acid, polycaprolactone, polyvinyl alcohol, hyaluronic acid) composites.
- Gradient materials, composites and hydrogels (CaP/polymer).



Group 2 – Drug/ion/cell delivery

- Local drug, biopharmaceuticals and functional ion, cell delivery systems (antimicrobials, bisphosphonates, growth factors, anti-inflammatory agents, functional ions and combinations of drugs/ions).



Group 3 – Materials *in vitro*

- Cellular responses, fundamental mechanisms that govern cell-biomaterial and cell-cell interactions.




Group 4 – Kinetics and stability of drug delivery systems

- Pharmaceutical technology from oral solid dosage forms to biomaterials as drug delivery systems.
- Active molecules and carrier particles - release kinetics and stability.



Group 5 – Preclinical evaluation of biomaterials

- *In vitro* and *in vivo* biocompatibility/cytotoxicity assays
- Kinetics of active substance release *in vitro*, bioavailability/pharmacokinetics *in vivo*.



Group 6 - Clinical evaluation of materials and personalized implant development.

- Clinical studies on biomaterials for bone regeneration, using 3D planning and printing technologies. Main fields - maxillofacial surgery and periodontology.